KR102716963B1 - 유도성 공발현 시스템에 사용을 위한 벡터 - Google Patents

유도성 공발현 시스템에 사용을 위한 벡터 Download PDF

Info

Publication number
KR102716963B1
KR102716963B1 KR1020187000942A KR20187000942A KR102716963B1 KR 102716963 B1 KR102716963 B1 KR 102716963B1 KR 1020187000942 A KR1020187000942 A KR 1020187000942A KR 20187000942 A KR20187000942 A KR 20187000942A KR 102716963 B1 KR102716963 B1 KR 102716963B1
Authority
KR
South Korea
Prior art keywords
gene
promoter
host cell
expression construct
inducible promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187000942A
Other languages
English (en)
Korean (ko)
Other versions
KR20180020213A (ko
Inventor
세아 맥클레인
마크 블라섹
필립 배리시
제레미 민셜
Original Assignee
에이비에스씨아이 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이비에스씨아이 코포레이션 filed Critical 에이비에스씨아이 코포레이션
Publication of KR20180020213A publication Critical patent/KR20180020213A/ko
Application granted granted Critical
Publication of KR102716963B1 publication Critical patent/KR102716963B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • General Factory Administration (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Slot Machines And Peripheral Devices (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020187000942A 2015-06-16 2016-06-16 유도성 공발현 시스템에 사용을 위한 벡터 Active KR102716963B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/740,475 2015-06-16
US14/740,475 US20150353940A1 (en) 2013-08-05 2015-06-16 Vectors for use in an inducible coexpression system
PCT/US2016/037942 WO2016205570A1 (en) 2015-06-16 2016-06-16 Vectors for use in an inducible coexpression system

Publications (2)

Publication Number Publication Date
KR20180020213A KR20180020213A (ko) 2018-02-27
KR102716963B1 true KR102716963B1 (ko) 2024-10-11

Family

ID=54769087

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187000942A Active KR102716963B1 (ko) 2015-06-16 2016-06-16 유도성 공발현 시스템에 사용을 위한 벡터

Country Status (12)

Country Link
US (2) US20150353940A1 (enExample)
EP (2) EP4039810A1 (enExample)
JP (2) JP6976860B2 (enExample)
KR (1) KR102716963B1 (enExample)
CN (1) CN107849572A (enExample)
AU (2) AU2016278242B2 (enExample)
CA (1) CA2986443A1 (enExample)
DK (1) DK3310919T3 (enExample)
ES (1) ES2906725T3 (enExample)
IL (2) IL307555A (enExample)
MX (1) MX390195B (enExample)
WO (1) WO2016205570A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106583A1 (en) * 2015-12-15 2017-06-22 Absci, Llc Cytoplasmic expression system
US12157766B2 (en) 2012-08-05 2024-12-03 Absci Corporation Cytoplasmic expression system
CA3114395A1 (en) 2018-09-25 2020-04-02 Absci, Llc Protein purification methods
KR20210090645A (ko) 2018-11-05 2021-07-20 제넨테크, 인크. 원핵 숙주 세포에서 2개의 사슬 단백질을 생산하는 방법
CN111269294B (zh) * 2018-12-05 2023-03-28 广州中国科学院先进技术研究所 纤维寡糖转运蛋白LacY的突变位点、突变转运蛋白LacY及其制备方法和应用
CN111979206B (zh) * 2019-05-24 2021-08-17 深圳瑞德林生物技术有限公司 固定化融合酶及用其制备谷胱甘肽的方法
AU2021312935B2 (en) * 2020-07-24 2024-11-28 Duke University Methods and compositions for the production of acetyl-CoA derived products
US20220380783A1 (en) * 2021-05-06 2022-12-01 Arizona Board Of Regents On Behalf Of Arizona State University Methods and system of managing resource competition in synthetic gene circuits
CN113528410A (zh) * 2021-06-23 2021-10-22 云舟生物科技（广州）有限公司 一种用于快速高效诱导表达外源蛋白的大肠杆菌工程菌及其制备方法与应用
WO2023114905A1 (en) 2021-12-16 2023-06-22 Absci Corporation Membrane-associated fusion proteins to increase the competency of cells
IL313521A (en) 2021-12-17 2024-08-01 Absci Corp Solid-phase screening for high-throughput bacterial strains
CN118510902A (zh) 2021-12-21 2024-08-16 Absci公司 用于鉴定具有增加的可溶性靶蛋白表达的菌株的FolA选择测定
EP4453198A1 (en) 2021-12-23 2024-10-30 ABSCI Corporation Products and methods for heterologous expression of proteins in a host cell
WO2023129881A1 (en) * 2021-12-30 2023-07-06 Absci Corporation Knockout of ptsp gene elevates active gene expression
US20230268026A1 (en) 2022-01-07 2023-08-24 Absci Corporation Designing biomolecule sequence variants with pre-specified attributes
WO2024006269A1 (en) 2022-06-29 2024-01-04 Absci Corporation Affinity screening method
WO2024040020A1 (en) 2022-08-15 2024-02-22 Absci Corporation Quantitative affinity activity specific cell enrichment
WO2024254237A1 (en) 2023-06-08 2024-12-12 Absci Corporation Solid-phase screening for high-performing bacterial strains
WO2025058962A1 (en) 2023-09-11 2025-03-20 Absci Corporation High-throughput methods for kinetic characterization, quantifying and optimizing antibodies and antibody fragments expression in bacteria
WO2025076081A1 (en) 2023-10-03 2025-04-10 Absci Corporation Tl1a associated antibody compositions and methods of use
WO2025122885A1 (en) 2023-12-08 2025-06-12 Absci Corporation Anti-her2 associated antibody compositions designed by artificial intelligence and methods of use
WO2025144700A1 (en) 2023-12-27 2025-07-03 Absci Corporation Nanobody library screening using bacterial surface display

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246542A1 (en) * 2001-08-27 2006-11-02 Genentech, Inc. System for antibody expression and assembly
US20090203081A1 (en) * 2005-07-01 2009-08-13 Keasling Jay D Inducible expression vectors and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3344618B2 (ja) 1997-06-20 2002-11-11 株式会社エイチ・エス・ピー研究所 シャペロン発現プラスミド
ATE449844T1 (de) * 1997-12-05 2009-12-15 Europ Lab Molekularbiolog Neue methode zur klonierung dns unter anwendung des e. coli rece/rect rekombinationssystems
US6780405B1 (en) 2000-04-28 2004-08-24 Avant Immunotherapeutics, Inc. Regulated antigen delivery system (RADS)
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
DE60135498D1 (de) * 2000-12-14 2008-10-02 Genentech Inc Produktion von ganzen Antikörpern in prokaryontischen Zellen
WO2005040388A2 (en) * 2003-08-22 2005-05-06 Nucleonics Inc. Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments
US8227241B2 (en) * 2004-03-12 2012-07-24 Unigene Laboratories, Inc. Bacterial host cell for the direct expression of peptides
DE102004061846A1 (de) * 2004-12-22 2006-07-13 Basf Ag Mehrfachpromotoren
CA2610405C (en) 2005-06-06 2015-01-27 Dow Global Technologies Inc. Mannitol induced promoter systems in bacterial host cells
EP2155789B1 (en) 2007-05-01 2013-07-24 Research Development Foundation Immunoglobulin fc libraries
US8999668B2 (en) 2008-01-03 2015-04-07 Cornell Research Foundation, Inc. Glycosylated protein expression in prokaryotes
KR100958096B1 (ko) * 2008-02-11 2010-05-14 한국과학기술원 염색체 특정 부위 제거용 재조합 벡터 및 이를 이용한미생물 내 염색체 특정 부위의 제거방법
DK2379722T3 (da) * 2008-12-16 2017-01-02 C-Lecta Gmbh Ekspressionsvektor
CA2754928A1 (en) * 2009-03-10 2010-09-16 Athena Biotechnologies, Inc. Reducing carbon dioxide production and increasing ethanol yield during microbial ethanol fermentation
US8623652B2 (en) * 2009-04-06 2014-01-07 Lucigen Corporation Host-vector system for cloning and expressing genes
AU2010322454B2 (en) * 2009-11-19 2016-05-19 Glaxosmithkline Biologicals S.A. Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
US8603797B2 (en) * 2010-03-17 2013-12-10 Cornell University Methods and compositions for targeted mutagenesis in bacteria
EP2386641A1 (en) 2010-05-11 2011-11-16 Université Catholique De Louvain Method for extracellular production of recombinant biomolecules in a microorganism
DK2880168T3 (en) * 2012-08-05 2017-04-18 Absci Llc INDUCERABLE CO EXPRESSION SYSTEM
EP3030651A4 (en) * 2013-08-05 2017-02-22 Aronora, Inc. Coordinated coexpression of thrombin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246542A1 (en) * 2001-08-27 2006-11-02 Genentech, Inc. System for antibody expression and assembly
US20090203081A1 (en) * 2005-07-01 2009-08-13 Keasling Jay D Inducible expression vectors and methods of use thereof

Also Published As

Publication number Publication date
CA2986443A1 (en) 2016-12-22
EP3310919A1 (en) 2018-04-25
AU2022228166A1 (en) 2022-09-29
US20150353940A1 (en) 2015-12-10
JP2018518957A (ja) 2018-07-19
IL256094A (en) 2018-02-28
US20160376602A1 (en) 2016-12-29
EP3310919B1 (en) 2021-12-15
IL256094B1 (en) 2023-11-01
AU2016278242B2 (en) 2022-06-09
JP2021153600A (ja) 2021-10-07
IL307555A (en) 2023-12-01
HK1253045A1 (zh) 2019-06-06
CN107849572A (zh) 2018-03-27
KR20180020213A (ko) 2018-02-27
JP6976860B2 (ja) 2021-12-08
US11371048B2 (en) 2022-06-28
DK3310919T3 (da) 2022-02-14
EP3310919A4 (en) 2019-01-09
EP4039810A1 (en) 2022-08-10
ES2906725T3 (es) 2022-04-20
WO2016205570A1 (en) 2016-12-22
AU2016278242A1 (en) 2018-01-18
MX390195B (es) 2025-03-20
MX2017016400A (es) 2018-03-02
IL256094B2 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
KR102716963B1 (ko) 유도성 공발현 시스템에 사용을 위한 벡터
AU2019202844B2 (en) Inducible coexpression system
KR102777327B1 (ko) 발효 공정
CN116083398B (zh) 分离的Cas13蛋白及其应用
US12157766B2 (en) Cytoplasmic expression system
US20220364104A1 (en) Vectors for use in an inducible coexpression system
HK40079399A (en) Vectors for use in an inducible coexpression system
BR112017026813B1 (pt) Construto de expressão, kit, célula hospedeira e método de produção de produto genético
BR122024008472A2 (pt) Construto de expressão, kit, célula hospedeira e método de produção de produto genético
US20040235121A1 (en) High copy number plasmids and their derivatives
HK1253045B (en) Vectors for use in an inducible coexpression system

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601